A part of Watch Media

MedWatchWednesday4 October 2023

Latest
Search
Log in

Pharma & biotech
Medtech
Hearing health
Regulation
Other

Search
Log in

MedWatchWednesday4 October 2023

Search
Log in

Pharma & biotech
Medtech
Hearing health
Regulation
Other

Top news from MedWatch this week

News about Genmab, Demant, Bavarian Nordic, Novo Nordisk, Snipr Biome, ALK, Eli Lilly, and Augmented Hearing.

Photo: MedWatch

by MIKKEL AABENHUS HEMMINGSEN

Monday

Genmab’s employee growth continues, reaches 2000 employees

How Demant will reach its climate goals: Electric cars, green power and supporting suppliers

Bavarian Nordic’s CFO puts faith in market research on multimillion-dollar chikungunya market

Tuesday

Novo Nordisk wants cardiovascular benefits of Wegovy approved

Jefferies: Cardiovascular study may increase pressure on authorities to reimburse Wegovy

Genmab invests heavily in artificial intelligence

Wednesday

Snipr Biome and Novo Nordisk extend collaboration

ALK reached out to main supplier after cases of safety and control breaches

Thursday

Cardiovascular study strengthens Novo Nordisk against Eli Lilly, says development chief

Novo Nordisk acquires Canadian biotech company for up to USD 1.1bn

Novo Nordisk books DKK 24bn operating profit and upgrades

Friday

Novo Nordisk chief: Inversago Pharma acquisition is ”a great addition to our pipeline”

Former Oticon veterans want to separate noise from conversation – now they’re seeking capital to grow

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

E-mail address

Newsletter terms

Front page now

Photo: Staff/Reuters/Ritzau Scanpix

Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
FDA approves Novo Nordisk drug to treat rare condition

Foto: Mike Blake

Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

For subscribers

Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers

Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr

Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers

Photo: Novo Nordisk / Pr

Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers

Foto: Stine Bidstrup

Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers

Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom
The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.
For subscribers
FDA approves Novo Nordisk drug to treat rare condition
The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.
For subscribers
Fujifilm expands management with former Leo executive
The contract manufacturer has hired a chief people officer with immediate effect.
For subscribers
Low share price may knock Galecto off the stock exchange
Nasdaq has requested that the biotech company raise its share price to above USD 1.
For subscribers
Snack maker keeps an eye on Novo Nordisk's obesity drug
”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.
Olympus appoints new chief medical officer
The new medical director is brought in from Medtronic.
For subscribers

Further reading

Foto: Mike Blake

Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers

Novo Nordisk's manufacturing facility in Clayton, the US. | Foto: Novo Nordisk/pr

Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers

Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr

Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers

Foto: Staff

Pharma & biotech

Novo Nordisk to sell Wegovy in the UK at a fraction of the US price

The price of weight loss drug Wegovy in the UK is completely different price than the in the US.

For subscribers

Foto: Alexander Heinl/AP/Ritzau Scanpix

Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

For subscribers

Foto: Tom Little

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Jobs

Clinical Trial Manager
Senior CMC Specialist, Upstream Processing, Genmab
Senior Analytical Scientists
VP of Software Development, Perfusion Tech
Clinical Supply Manager
Scientist - Bioanalysis, Biologics
Chemist for Incoming Materials in QC department
QA/RA Manager
Supply Value Stream (SVS) Project Manager
Global Medical Manager
Senior QA Specialists (GMP or GCP)
Audit & Supplier Manager
Qualified Person to AJ Vaccines
Discovery Project Leader, Principal Scientist
Project Director, HR & ESG
Director, Head of Antibody Technology
Senior Legal Councel

Latest news

Novo Nordisk suffers Wegovy defeat to Viatris in patent court –
Pharmaceutical industry to grow 4% annually towards 2030 –
Zealand Pharma CEO: "We've never been stronger" –
Eli Lilly's head of diabetes and obesity retires –
DNB expects ALK's tablet sales to recover in 2024 –
Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees –
Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom –
Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
Olympus appoints new chief medical officer –
Low share price may knock Galecto off the stock exchange –

Jobs

Clinical Trial Manager
Senior CMC Specialist, Upstream Processing, Genmab
Senior Analytical Scientists
VP of Software Development, Perfusion Tech
Clinical Supply Manager
Scientist - Bioanalysis, Biologics
Chemist for Incoming Materials in QC department
QA/RA Manager
Supply Value Stream (SVS) Project Manager
Global Medical Manager
Senior QA Specialists (GMP or GCP)
Audit & Supplier Manager
Qualified Person to AJ Vaccines
Discovery Project Leader, Principal Scientist
Project Director, HR & ESG
Director, Head of Antibody Technology
Senior Legal Councel

Colophon

Sections

Pharma & biotech
Medtech
Hearing health
Regulation
Other
Sitemap
RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

Privacy Policy

Copyright © MedWatch — All rights reserved